biotech

Anthropic reported that using about 950 Claude agents over 21 hours identified a potential biological lead in enzyme research, but the result is preliminary and raises questions about validating AI agent workflows in science.

Anthropic announced that its AI model Claude has discovered a novel enzyme system, marking a significant advancement in AI-driven scientific research.

Emma Waters, a conservative writer, pushes for regulation of reproductive technology, highlighting ethical issues in the fertility industry and tech advancements like embryo editing.

This article outlines five millennium-style grand challenges for biology, including demonstrating the origin of life, cryopreserving live mice, reverse translation of peptides, enhancing Rubisco enzymes, and engineering cells with non-standard genetic codes.

Boriss is building a DNA printer, as announced in a social media post.

MIT Technology Review addresses AI's extinction risk and the threat of AI-enabled bioweapons, featuring Q&A from a live event and discussions on biotech safety.

Anthropic has quietly established a biology lab to advance its AI-driven drug discovery program.

The article discusses warnings from AI leaders about the risk of AI enabling bioweapon creation, highlighting concerns from researchers and the need for enhanced safeguards in AI and biotech development.

The article covers research on mice with part-human brains and features young innovators in climate tech from MIT Technology Review, with a mention of proposed nuclear-style AI safeguards by US and Chinese experts.

Arc Institute is hiring experts in disease biology, computational biology, functional genomics, and NGS for its Tech Centers and Core Labs, with various roles based in Palo Alto.

Eli Lilly has acquired AtaiBeckley, a psychedelics biotech company founded by Christian Angermayer, for up to $3.8 billion, marking the largest transaction in the psychedelic sector.

MIT Technology Review highlights young biotech innovators with breakthroughs in therapy and gene editing, and a founder developing a cheaper, cleaner steelmaking process.

MIT Technology Review features five young innovators under 35 working on groundbreaking biotech projects, including a postpartum hemorrhage device, advanced brain electrodes, personalized gene-editing therapy, age-reversal eye treatment, and AI-designed viruses.

OpenAI has shut down a protein design project, prompting the user to turn to open weight models for biological research.

Google DeepMind's AlphaGenome Atlas is an AI-powered map of all possible single-letter DNA mutations, providing a 1-petabyte dataset for researchers to explore genetic variants via a free web interface and API.

An experimental AI-created drug, Rentosertib, unexpectedly reduced patients' biological age indicators by about 6 years during trials for idiopathic pulmonary fibrosis.

This essay argues that slow and costly U.S. clinical trials—not scientific limitations—are now the biggest obstacle to curing cancer and deploying AI-driven personalized therapies, urging regulatory reform as China and Australia outpace American drug development.

A patient has lived with a transplanted pig kidney for a record-setting nine months, demonstrating the potential of xenotransplantation to address organ shortages. The achievement leverages CRISPR gene editing by eGenesis, with published research in The Lancet aiding further improvements.

TxBench is a benchmark for antibody discovery, likely assessing computational or AI-driven methods in this biotech domain.

This newsletter from MIT Technology Review covers a secretive antiaging drug from Generation Lab, provides guidance on joining virtual power plants, and reports on a judge blocking the Pentagon's blacklisting of Anthropic.